Search
VY-HTT01
go.drugbank.com/drugs/DB16999InvestigationalVY-HTT01 is comprised of an adeno-associated virus capsid (AAV1) and a proprietary transgene that harnesses the canonical RNA interference pathway to selectively knock down levels of HTT mRNA.
RO7300490
go.drugbank.com/drugs/DB17535InvestigationalRO7300490 is an investigational Fibroblast Activation Protein-α (FAP) targeted CD40 agonist.
FB-825
go.drugbank.com/drugs/DB17598InvestigationalFB-825 is an investigational humanized monoclonal antibody that targets the CεmX domain of the membrane-bound IgE (mIgE), causing a depletion of mIgE positive B-cells.
LM-609
go.drugbank.com/drugs/DB05787ExperimentalLM-609 (Vitaxin) is an artificial antibody that targets a protein on the surface of newly forming blood vessels, as well as on certain tumors.
Satraplatin
go.drugbank.com/drugs/DB04996InvestigationalAs an investigation drug, it has not yet received U.S. Food and Drug Administration (FDA) approval and is not available in retail pharmacies.
Saprisartan
go.drugbank.com/drugs/DB01347ExperimentalSaprisartan is an AT1 receptor antagonist. It is based on medications of losartan's prototypical chemical structure.
KIN-3248
go.drugbank.com/drugs/DB17587InvestigationalKIN-3248 is a small molecule that targets and inhibits oncogenic fibroblast growth factor receptors (FGFRs). It was designed to mainly target FGFR2 and FGFR3 alterations, which act as oncogenic drivers in 10-20% of cholangiocarcinoma and...
PGX-100
go.drugbank.com/drugs/DB06114InvestigationalPGX-100 is an intravenous dosage form of modified heparin.
3-fluoro-N-1H-indol-5-yl-5-morpholin-4-ylbenzamide
go.drugbank.com/drugs/DB08092ExperimentalThese are aromatic compounds containing a morpholine ring and a benzene ring linked to each other through a CC or a CN bond. This drug targets mitogen-activated protein kinase 14.